Stock Price, News, Quote and Profile of ADAMIS PHARMACEUTICALS CORP(NASDAQ:ADMP) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ADAMIS PHARMACEUTICALS CORP

NASDAQ:ADMP (9/7/2023, 7:00:00 PM)

After market: 0.77 -0.01 (-0.66%)

0.7751

+0.01 (+0.86%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap2.16M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. Its products in the allergy, respiratory and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg, SYMJEPI (epinephrine) Injection 0.15mg and ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL. SYMJEPI (epinephrine) Injection 0.3mg is approved by the United States Food and Drug Administration (FDA) for use in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more. SYMJEPI (epinephrine) Injection 0.15mg is approved by the FDA for use in the treatment of anaphylaxis for patients weighing 33-65 pounds. ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL is approved by the FDA for the treatment of opioid overdose. The firm's Tempol, is an investigational drug.

Company Info

ADAMIS PHARMACEUTICALS CORP

Suite 310, 11455 El Camino Real

San Diego CALIFORNIA 92130

P: 18589972400.0

CEO: Dennis J. Carlo

Employees: 11

Website: https://www.adamispharmaceuticals.com/

ADMP News

8 months ago - Seeking AlphaAdamis changes name to DMK Pharmaceuticals, ticker to DMK (NASDAQ:ADMP)

Adamis Pharmaceuticals (ADMP) is changing its name to DMK Pharmaceuticals (DMK) and its Nasdaq ticker symbol to DMK. Read more here.

8 months ago - Adamis Pharmaceuticals CorporationAdamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus

Company to begin trading under new ticker symbol “DMK” on September 8, 2023...

8 months ago - Adamis Pharmaceuticals CorporationAdamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today...

9 months ago - Adamis Pharmaceuticals CorporationAdamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering

SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today...